Clinical genetic testing for familial melanoma in Italy: A cooperative study - 07/08/11
⁎ 
, Paola Ghiorzo, PhD a, , Linda Battistuzzi, MS a, , Paolo A. Ascierto, MD b, Monica Barile, MD c, Sara Gargiulo, PhD a, Francesca Gensini, MD d, Sara Gliori, MD a, Michele Guida, MD e, Maurizio Lombardo, MD f, Siranoush Manoukian, MD g, Chiara Menin, PhD h, Sabina Nasti, PhD a, Paola Origone, PhD a, Barbara Pasini, MD i, Lorenza Pastorino, PhD a, Bernard Peissel, MD g, Maria Antonietta Pizzichetta, MD j, Paola Queirolo, MD k, Monica Rodolfo, PhD g, Antonella Romanini, MD l, Maria Chiara Scaini, PhD m, Alessandro Testori, MD n, Maria Grazia Tibiletti, MD o, Daniela Turchetti, MD p, Sancy A. Leachman, MD q, Giovanna Bianchi Scarrà, PhD aIMI, the Italian Melanoma Intergroup
Correspondence to: William Bruno, MD, PhD.Abstract |
Background |
The Italian Society of Human Genetics’ (SIGU) recommendations on genetic counseling and testing for hereditary melanoma state that clinical genetic testing can be offered to Italian melanoma families with at least two affected members.
Objective |
In the framework of a cooperative study, we sought to establish the frequency of cyclin-dependent kinase inhibitor 2A mutations in melanoma families that underwent clinical genetic counseling and testing in accordance with the SIGU recommendations at 9 centers in different Italian regions.
Methods |
Cyclin-dependent kinase inhibitor 2A testing was conducted by direct sequencing and multiplex ligation-dependent probe amplification analysis in melanoma families with at least two affected members.
Results |
A total of 33% (68/204) of the families harbored cyclin-dependent kinase inhibitor 2A mutations. In the 145 families with two affected members the mutation frequency was 25%. Three novel mutations, L94P, A86T, and c.407dupG, were identified among the cases and not in 200 controls.
Limitations |
We were unable to perform separate analyses for individual centers, as in some cases the number of families was too small.
Conclusions |
The availability of clinical genetic testing for melanoma to families with just two affected members in the same branch is justified in Italy in terms of the likelihood of identifying a mutation.
Le texte complet de cet article est disponible en PDF.Key words : cyclin-dependent kinase 4, cyclin-dependent kinase inhibitor 2A, familial melanoma, genetic testing
Abbreviations used : AAD, CDK4, CDKN2A, GenoMEL, MPM, SIGU
Plan
| Supported by the International Melanoma Genetics Consortium 01872 Network of Excellence Grant to Dr Bianchi Scarra’; Dr Scaini is supported by a Fondazione Italiana per la Ricerca sul Cancro (FIRC) fellowship. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 61 - N° 5
P. 775-782 - novembre 2009 Retour au numéro
Article précédent
- Large congenital melanocytic nevi and neurocutaneous melanocytosis: One pediatric center’s experience
- Audrey Lovett, Catherine Maari, Jean-Claude Decarie, Danielle Marcoux, Catherine McCuaig, Afshin Hatami, Pascal Savard, Julie Powell
- Exposure to mass media health information, skin cancer beliefs, and sun protection behaviors in a United States probability sample
- Jennifer Hay, Elliot J. Coups, Jennifer Ford, Marco DiBonaventura
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?